Drug Trial Radar · NCT07422285
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Jan 16, 2026
Primary completion
Jul 24, 2026
Study completion Jul 31, 2026
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Feb 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this trial is to evaluate the pharmacokinetics of two evolocumab drug products in healthy participants.
Conditions
- Healthy Participants
- Pharmacokinetics
Interventions
Evolocumab Drug Substance ADrug
Evolocumab drug substance A will be administered SC.
Evolocumab Drug Substance BDrug
Evolocumab drug substance B will be administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Concentration-time Curve (AUC) from Time 0 Extrapolated to Infinity (AUCinf) of EvolocumabTime frame: Day 1 to Day 64
- Area Under the Concentration-time Curve from Time 0 to Time of Last Quantifiable Concentration (AUClast) of EvolocumabTime frame: Day 1 to Day 64
- Maximum Observed Concentration (Cmax) of EvolocumabTime frame: Day 1 to Day 64
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
QPS Bio-Kinetic
Springfield, Missouri
Ohio Clinical Trials, Inc.
Columbus, Ohio
Fortrea Clinical Research Unit - Dallas
Dallas, Texas
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.